Healthy Skepticism Library item: 20557

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Moynihan R
Under the microscope
The Australian Financial Review 2002 July 1280
http://www.accessmylibrary.com/coms2/summary_0286-25921057_ITM

Abstract:

Two products manufactured by the multinational pharmaceutical company, AstraZeneca, are in question. One of the products is the cholesterol-lowering drug, Crestor, which has failed to receive the approval of the US Food and Drug Administration due to safety concerns. The other product is the stomach and heartburn drug, Nexium, which is having its effectiveness questioned. The two drugs promised the London-based company potential sales of more than $A10bn a year. AstraZeneca has a market capitalisation of about $A120bn.